ReviewDiscover oncology2025
Emerging strategies for targeting vasculogenic mimicry in breast cancer treatment.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Association of Post-Neoadjuvant Chemotherapy MRI andDiagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer represents the most commonly diagnosed malignancy worldwide and is the fourth leading cause of cancer-related mortality. Approximately 2.3 million new cases of breast cancer were diagnosed worldwide in 2022, accounting for 11.6% of all cancer cases, with approximately 670,000 associated deaths. Breast tumors frequently present with abnormal and highly vascularized networks, promoting accelerated growth and contributing to metastatic potential. Increased vascularization often indicates a more aggressive cancer and significantly affects breast cancer treatment. While angiogenesis offers potential therapeutic targets, it also complicates treatment strategies. Anti-angiogenic drugs such as bevacizumab, which target vascular endothelial growth factor-A signaling, have shown potential in limiting tumor growth. However, their success has been limited, as tumors can develop resistance through alternative pathways. Aggressive breast cancer cells, regardless of estrogen-receptor status, can form vessel-like structures through vasculogenic mimicry. This phenomenon also enables them to evade anti-angiogenic treatment and contributes significantly to tumor resistance to various therapeutic interventions. Moreover, vasculogenic mimicry-positive breast cancer patients exhibit high tumor grade, increased invasiveness, metastasis, and poorer survival outcomes as compared to vasculogenic mimicry-negative breast cancer patients. At present, there are no clinically approved therapies that specifically target vasculogenic mimicry in breast cancer. The intricate molecular mechanisms involved in vasculogenic mimicry within breast cancer present considerable challenges to the development of effective therapeutic strategies. Achieving therapeutic breakthroughs that address this phenomenon would represent a major step in the management of breast cancer. This review examines key molecular pathways that regulate vasculogenic mimicry in breast cancer and assesses the potential of targeting vasculogenic mimicry for therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.